服用螺内酯的慢性心力衰竭患者经历的严重不良事件。
Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
作者信息
Berry C, McMurray J J
机构信息
Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK.
出版信息
Heart. 2001 Apr;85(4):E8. doi: 10.1136/heart.85.4.e8.
Abstract
In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia. In some cases this seems to happen because spironolactone causes diarrhoea. Four cases involving men with New York Heart Association functional class III heart failure are presented. As these cases revealed, close monitoring of blood chemistry is mandatory after starting spironolactone, and patients should be advised to stop spironolactone immediately if diarrhoea develops.
摘要
在慢性心力衰竭患者中，在常规治疗基础上加用螺内酯可能会导致严重的，偶尔甚至是致命的高钾血症。在某些情况下，出现这种情况似乎是因为螺内酯导致腹泻。本文介绍了4例纽约心脏协会心功能Ⅲ级的男性心力衰竭患者的病例。正如这些病例所显示的，开始使用螺内酯后必须密切监测血液生化指标，并且应建议患者如果出现腹泻应立即停用螺内酯。
相似文献
1
Serious adverse events experienced by patients with chronic heart failure taking spironolactone.服用螺内酯的慢性心力衰竭患者经历的严重不良事件。
Heart. 2001 Apr;85(4):E8. doi: 10.1136/heart.85.4.e8.
2
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).在血管紧张素转换酶抑制剂和袢利尿剂基础上加用螺内酯治疗重度慢性充血性心力衰竭的疗效（随机螺内酯评估研究[RALES]）
Am J Cardiol. 1996 Oct 15;78(8):902-7. doi: 10.1016/s0002-9149(96)00465-1.
3
New therapy update. Inspra (eplerenone tablets).新疗法更新。因spra（依普利酮片）。
Congest Heart Fail. 2003 Nov-Dec;9(6):341-2. doi: 10.1111/j.1527-5299.2003.03306.x.
4
Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.危及生命的高钾血症：一名肾功能不全患者因使用螺内酯治疗心力衰竭而引发的并发症。
Anesth Analg. 2002 Jul;95(1):39-41, table of contents. doi: 10.1097/00000539-200207000-00006.
5
Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.螺内酯在心力衰竭患者中的应用致高钾血症和急性肾损伤。
Mayo Clin Proc. 2020 Nov;95(11):2408-2419. doi: 10.1016/j.mayocp.2020.03.035.
6
Spironolactone in the treatment of congestive heart failure.
Ann Pharmacother. 2000 Nov;34(11):1336-40. doi: 10.1345/aph.10104.
7
[Effects of the RALE study. Hyperkalemia following spironolactone treatment].[RALES研究的效果。螺内酯治疗后高钾血症]
Internist (Berl). 2005 Apr;46(4):466, 468. doi: 10.1007/s00108-005-1365-1.
8
The safety of spironolactone treatment in patients with heart failure.螺内酯治疗心力衰竭患者的安全性。
J Clin Pharm Ther. 2003 Aug;28(4):285-7. doi: 10.1046/j.1365-2710.2003.00491.x.
9
Hyperkalaemia in the age of aldosterone antagonism.醛固酮拮抗剂时代的高钾血症。
QJM. 2012 Nov;105(11):1049-57. doi: 10.1093/qjmed/hcs106. Epub 2012 Jun 20.
10
Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.用于治疗高血压和心力衰竭的盐皮质激素受体拮抗剂
Methodist Debakey Cardiovasc J. 2015 Oct-Dec;11(4):235-9. doi: 10.14797/mdcj-11-4-235.
引用本文的文献
1
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.比较心力衰竭中醛固酮受体拮抗剂的疗效和安全性：一项随机对照试验的网络荟萃分析。
Heart Fail Rev. 2019 Sep;24(5):637-646. doi: 10.1007/s10741-019-09790-5.
2
Mineralocorticoid receptor antagonists for heart failure: a real-life observational study.醛固酮受体拮抗剂治疗心力衰竭：一项真实世界观察性研究。
ESC Heart Fail. 2018 Jun;5(3):267-274. doi: 10.1002/ehf2.12244. Epub 2018 Feb 4.
3
The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.依普利酮在血液透析患者中的安全性：一项非劣效性随机对照试验。
Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1602-8. doi: 10.2215/CJN.12371214. Epub 2015 Jul 2.
4
Effects of low-dose spironolactone combined with irbesartan on cardiac hypertrophy induced by pressure overload in rats.低剂量螺内酯联合厄贝沙坦对大鼠压力超负荷诱导的心肌肥厚的影响。
Am J Transl Res. 2014 Nov 22;6(6):809-19. eCollection 2014.
5
Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.在轻度至中度慢性心力衰竭患者中额外使用醛固酮拮抗剂：系统评价和荟萃分析。
Br J Clin Pharmacol. 2013 May;75(5):1202-12. doi: 10.1111/bcp.12012.
6
Safety of spironolactone use in ambulatory heart failure patients.安体舒通在门诊心力衰竭患者中的使用安全性。
Clin Cardiol. 2008 Nov;31(11):509-13. doi: 10.1002/clc.20284.
7
Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.慢性心力衰竭患者中螺内酯的耐受性——一则警示信息。
Br J Clin Pharmacol. 2004 Nov;58(5):554-7. doi: 10.1111/j.1365-2125.2004.02187.x.
8
Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.螺内酯对已接受最佳治疗的轻度心力衰竭患者内皮功能、血管紧张素转换酶活性及其他预后标志物的影响。
Heart. 2004 Jul;90(7):765-70. doi: 10.1136/hrt.2003.017368.
9
Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.螺内酯与血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的相互作用：44例分析。
BMJ. 2003 Jul 19;327(7407):147-9. doi: 10.1136/bmj.327.7407.147.
10
Nephrotoxicity in the elderly due to co-prescription of ACE inhibitors and NSAIDs.老年患者因同时使用血管紧张素转换酶抑制剂和非甾体抗炎药导致的肾毒性。
J R Soc Med. 2001 Dec;94(12):657-8. doi: 10.1177/014107680109401228.
本文引用的文献
1
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.螺内酯对重度心力衰竭患者发病率和死亡率的影响。随机螺内酯评估研究调查组。
N Engl J Med. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001.
2
Hyperkalemia and hyporeninemic hypoaldosteronism.高钾血症与低肾素性低醛固酮血症
Kidney Int. 1980 Jan;17(1):118-34. doi: 10.1038/ki.1980.14.
3
Consequences of fluid loss in patients treated with ACE inhibitors.使用血管紧张素转换酶抑制剂治疗的患者体液流失的后果。
Postgrad Med J. 1987 May;63(739):385-7. doi: 10.1136/pgmj.63.739.385.
Zotero 插件